Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2022 Jan 1;89(1):49–55. doi: 10.1097/QAI.0000000000002821

Table 2:

Adjusted Odds Ratios from logistic regression models comparing individuals selected under each prioritization scheme in 2015 to those in clusters at 1.5% (2101 individuals, 517 clusters, 8.4 percent increase).

Clustering Relative Growth Recent and Rapid Growth
c1% c0.5% g1.5% g1% g0.5% RR2 RR3 RR4 RR5
 
Number of priority clusters 407 269 3 5 24 71 27 14 7
Number of cases to be prioritized 1499 838 158 154 152 283 161 94 51
Percent increase 17.2 15.8 26.6 27.9 36.2 31.8 41.6 39.4 45.1
 
AGE AT DIAGNOSIS
14 - 19 4.1*** 2.85*** 2.22** 3.02**
20 - 24 2.8*** 2.04** 1.64*
25 - 29 REF REF REF REF REF REF REF REF REF
30 - 39
40 - 49
50 - 100 0.57*
 
RACE/ETHNICITY
African American 0.62** 0.55* 0.6** 0.6*
Latino 0.52* 0.09**
White REF REF REF REF REF REF REF REF REF
Unknown
 
SEX/RISK GROUP
MSM 1.51* 6.43** 2.16* 4.06* 7.6*
Female heterosexual REF REF REF REF REF REF REF REF REF
Female PWID 0.28*
Female unknown risk
Male heterosexual
Male PWID
MSM/PWID 6.84*
Male unknown risk

Cluster prioritization schemes are defined in Table 1. Results are shown only if they were significant (p<0.05).

*

p<0.05

**

p<0.01

***

p<0.001. MSM: men who have sex with men, PWID: people who inject drugs.